Latest Advanced Prostate Cancer News2025-03-09T11:34:54-04:00

Dendreon (Provenge) Initiates Second of Two New Phase 2 Trials

Dendreon Corporation (Nasdaq: DNDN), the company that is testing Provenge a potential vaccine for prostate cancer, has started a second of two new Phase 2 trials. The multicenter trial, called ProACT (PROstate Active Cellular Therapy), [...]

Go to Top